Paget's disease (PD) of the breast is rare, accounting for 1--3% of all breast malignancies. Paget's disease is characterized by the eczematous eruption and ulceration of the nipple or areola[@b1][@b2][@b3]. Due to its rare occurrence, diagnosis of PD may be a delayed or misdiagnosed as benign dermatosis. Breast imaging examination should be used to identify the presence of concomitant breast cancer, and nipple skin biopsy may provide further definitive diagnosis.

In the majority of patients, PD has been found in association with invasive breast cancer or ductal carcinoma *in situ*, with concomitant disease identified in up to 82% to 93%[@b4][@b5]. Additionally, several studies have found Paget's disease with invasive ductal carcinoma (PD-IDC) to be associated with tumours that are larger in size and higher in grade as well as negative oestrogen receptor (ER) and progesterone receptor (PR) but positive human epidermal growth factor receptor 2 (Her2) status. Further, diagnosis of PD-IDC may be associated with reduced survival[@b6][@b7][@b8][@b9].

Traditional treatment for PD-IDC has been mastectomy due to the common occurrence of sonographically and mammographically hidden multifocal and multicentric malignancies located in breast tissue far from the nipple. However, with the development of imaging technology, breast conservation surgery (BCS) has been found to be a feasible surgical option with low risk for local recurrence in selected patients[@b5][@b10][@b11]. In addition to BCS, sentinel lymph node biopsy (SLNB) may be effective in patients with PD; however, its role in PD treatment remains unclear. Based on current standards, SLNB has been recommended as a less invasive method than axillary lymph node dissection (ALND) for the staging of patients with early IDC. We speculate SLNB may be effective in detecting ALNs in patients with PD-IDC as well.

For these reasons, the aim of this study was to analyse the clinical presentation, treatment and outcome in patients with PD-IDC, with special emphasis on the role of BCS and SLNB in PD-IDC treatment.

Results
=======

Clinical and Tumour Characteristics
-----------------------------------

A total of 180253 breast cancer patients were eligible during the 2010--2013 study period. We excluded from the analysis 617 patients whose survival times were classified as unknown. A total of 179776 IDC and 477 PD-IDC patients had information available and were included in this study.

Differences in patient demographics, cancer characteristics, treatments, and outcomes between histological subgroups are summarized in [Table 1](#t1){ref-type="table"}. Compared with IDC, patients with PD-IDC were more likely to have more lymph node involvement and tumours of a higher grade, more advanced stage, and larger size (each P \< 0.05). PD-IDC tumours were more likely to be HR-negative and Her2-positive when compared with IDC tumours. Among the treatment options, patients with PD-IDC were more likely to undergo a mastectomy and axillary lymph node dissection but less likely to undergo radiotherapy when compared with IDC patients (P \< 0.05).

Survival Analysis
-----------------

Weighted Kaplan-Meier analysis was used to determine OS and BCSM within histological subgroups. At a follow-up time, patients with PD-IDC had an OS of 89.5%, while patient sin the IDC group had an OS of 92.8% (P \< 0.05). Further, the BCSM rate was 7.4% within the PD-IDC group compared with 4.5% within the IDC group (P \< 0.05) ([Table 1](#t1){ref-type="table"}). However, patients with PD-IDC had a better prognosis and lower mortality compared with the IDC group in adjusted analyses ([Fig. 1](#f1){ref-type="fig"}). Due to tumour heterogeneity and sample capacity disparity, these may prevent the robustness of the conclusions[@b12]. Then, we generated 3 independent cohorts by randomly selecting considerable samples from the entirety. Each cohort was required to maintain the same ratio of various factors as that of the original set, without sample overlap among the cohorts. We further analysed the clinicopathologic features and performed survival curves compared each cohort to PD-IDC group ([Supplementary 1 and 2](#S1){ref-type="supplementary-material"}). And the results further revealed that patients with PD-IDC had a better prognosis compared with those with IDC.

We performed multivariate analysis to evaluate prognostic factors of OS and BCSM in cases with PD-IDC ([Table 2](#t2){ref-type="table"}). In the multivariate model, tumour stage and history of LN surgery were significantly associated with OS, while age at diagnosis, tumour stage and Her2 status were associated with BCSM (P \< 0.05). Among patients, Her2 positive cancer was significantly associated with a higher rate of BCSM, as showed in [Fig. 2](#f2){ref-type="fig"} (OS, P = 0.217, aHR = 2.096; BCSM, P = 0.024, aHR = 5.169).

Effect of Surgical Treatment on Survival Outcomes
-------------------------------------------------

For patients with PD-IDC, the results of multivariate analysis suggested that SLNB was significantly associated with OS during the follow-up period (P = 0.028). Further, we analysed survival outcomes by surgical treatment subgroups. We defined two subgroups based on different surgical treatments: one included patients who underwent BCS with radiotherapy and mastectomy (M), and the other was separated into M + ALND, M + SLNB, BCS + ALND and BCS + SLNB. The results demonstrated no difference between these subgroups for OS or BCSM ([Fig. 3](#f3){ref-type="fig"}).

Discussion
==========

In this large population-based cohort of cases diagnosed with PD-IDC, we identified improved survival when adjusting for other factors relative to patients with IDC alone. In addition, our analysis of Her2 status demonstrated the PD-IDC patients with Her2 positive cancer were at significantly greater risk of BCSM, as were patients with advanced tumour stage. In our series, there was no difference between surgical treatment subgroups.

In the current study, patients with PD-IDC tended to have a more extensive lymph node involvement and distant metastases and tumours that were higher in grade, more advanced in stage, larger in size, and more frequently HR-positive and that had higher levels of Her2 expression compared to those with IDC. Kothari *et al*.[@b13] reported that patients with PD-IDC had a significantly lower survival (10-year OS 49%) than patients with IDC only (64%). They attributed the poorer survival outcomes in patients with PD-IDC to higher levels of Her2-positive expression. Further, they compared the survival of patients with PD to the survival of those with IDC after adjusting for Her2 status and other factors. When controlling for Her2 status, the two groups had a similar OS. However, we analysed common prognostic factors as well as Her2 status. The results showed that patients with PD-IDC had significantly better survival outcomes than those with IDC alone, and patients with Her2-positive cancer had a higher BCSM but similar OS to patients with Her2-negative cancer after adjusting for other prognostic factors. This result differed from Kothari's study, and this discrepancy may be due to the inclusion of different variables within the two studies. For instance, we included HR status and history of SLNB as variables within our analyses.

Surgical treatment of PD-IDC has been controversial. Historically, patients with PD were predominately treated with mastectomy for two main reasons: the high incidence of potential multifocality and contraindication for BCS patients with centrally located breast cancer. Several studies have revealed that local excision alone was not an appropriate surgical approach for patients with PD of the nipple[@b3][@b10]. However, the consensus has been that BCS may be effective in selected patients. The previously reported techniques for BCS in patients with PD have varied widely and include nipple excision and central segmentectomy as well as resection plus radiation. There is a place for BCS in selected patients with PD of the breast, especially those with no mass. Long-term follow-up of patients with PD following BCS with radiotherapy has only once been previously reported[@b14]. This study found that breast cancer-specific survival (BCSS) rate was 91%, 83%, and 76% at 5, 10, and 15 years, respectively. In an analysis using SEER data, Chen *et al*. found a 15-year BCSS up to 61% (95% CI, 53--68%) in patients with PD-IDC diagnosed between 1988 and 2002. Further, there was no statistically difference in survival between central lumpectomy and mastectomy after adjusting for tumour characteristics[@b6]. Similarly, these studies supported the use of BCS with radiotherapy as a feasible alternative for patients with PD-IDC. Although SLNB may still be considered a controversial treatment in patients with PD, SLNB has become a common approach in patients with breast cancer and appears to be a feasible treatment option[@b15][@b16]. When IDC has been identified and a mastectomy has been completed, SLNB should still be routinely employed in axillary node negative DCIS patients[@b17][@b18]. In the present study, patients undergoing SLNB had similar survival to those receiving ALND regardless of surgical mode of their breast cancer treatment. Current National Comprehensive Cancer Network (NCCN) guidelines encouraged axillary staging in patients with PD-IDC, while axillary assessment was not found to be necessary for PD-DCIS undergoing BCS[@b19][@b20]. Further study regarding the potential benefits of SLNB in patients with PD-IDC is warranted.

A previous examination of the molecular profiles of PD suggest that the luminal B subtype was most frequently identified[@b21]; however, other studies have reported the HER2-positive (nonluminal) subtype to be more common in primary PD[@b22]. Some studies have found that tumours in patients with PD were positive for c-erbB-2, cyclin D1, Ki-67 and p16, which have been associated with more aggressive tumour behaviour, and simultaneously had low level expression of Bcl-2 or ER and PR, which has been associated with a better prognosis[@b21][@b23]. Additional molecular studies are required, and differences in survival outcomes must continue to be monitored.

The main limitations of this study were a small sample size, heterogeneous population and retrospective methodology. The information regarding systemic therapy was insufficient, and follow-up was limited. This may have impacted our results, as Her2-targeted therapy and novel adjuvant radiation may significantly improve survival when fully utilized in the management of PD. Additionally, this study did not include specific information regarding the type of axillary operation and thus used number of lymph nodes excised as a proxy.

Despite these limitations, our study demonstrated that PD-IDC appears to alter the association between prognosis and HER2 status. Meanwhile, BCS with radiotherapy may be a feasible treatment alternative, as it resulted in survival rates similar to those achieved with mastectomy, and SLNB should be considered as an appropriate treatment for patients with PD-IDC. However, surgical treatment plans should be selected based on the results of clinical and imaging assessments. Further studies are needed to minimize variation in treatment of PD-IDC and to establish a standardized management approach for PD-IDC.

Materials and Methods
=====================

Data source and study design
----------------------------

We obtained data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) programme database collected between 2010 and 2013. Her2 status was initially collected by SEER in 2010; therefore, we used 2010 as the starting point for our study. We used the *International Classification of Diseases for Oncology*, 3rd edition (ICD-O-3) histopathology codes to extract data for all cases with Paget's disease with invasive ductal carcinoma (PD-IDC) (code 8541). Data from patients with ductal carcinoma of no special type (ICD-O-3 code 8500) was obtained to serve as a control group. We selected cases with known hormone receptor (HR) and Her2 status. Patients who did not receive surgery, had ICD of unknown type or were diagnosed at autopsy were excluded.

Type of surgery were categorized as BCS (primary site surgery codes 20--24) of mastectomy (primary site surgery codes 30--80). Because the type of axillary surgery was not reported within SEER, removal of 1--5 lymph nodes was regarded as sentinel lymph node biopsy (SLNB) and removal of \>5 lymph nodes removed was regarded as axillary lymph node dissection (ALND), as in previous studies[@b24].

Demographic variables included age at diagnosis (\<35, 35--49, 50--64, \>65 years) and race (white, black, other). Cancer characteristics included stage (I, II, III, IV, unknown), grade (well, moderately, poorly, undifferentiated, unknown), T stage (T0/T1, T2, T3, T4, NA), N stage (N0, N1, N2, N3, NX, NA), distant metastasis (M0, M1, NA), laterality (right, left, paired, bilateral, unknown), and HR and Her2 status (positive, negative, borderline, unknown). Receipt of radiation therapy (no, yes, unknown) was collected to characterize treatment. Tumour subtypes were characterized by a breast subtype variable and defined as HR+/Her2−, HR+/Her2+, HR−/Her2+ and triple-negative (TN).

The two main outcomes in our study were overall survival (OS) and breast cancer-specific mortality (BCSM). Vital status was recorded as "alive" or "dead" in the SEER dataset. Survival time (in months) was calculated for each patient using the "Completed Months of Follow-up" variable in the SEER database. Overall survival (OS) was determined by the proportion of patients alive at the end of the study period or their last follow-up. Breast cancer-specific mortality (BCSM) was determined by the proportion of patients whose cause of death was due to breast cancer relative to that of patients who were alive at the end of the study period or their last follow-up or died due to other causes. Cases without survival times were classified as unknown and removed from the study.

Statistical analysis
--------------------

Patient demographics and cancer- and treatment-related characteristics were compared between histological subgroups using chi-square or Fisher's exact tests. Survival outcomes (OS and BCSM) were estimated using the weighted Kaplan--Meier method, and variables were compared between histological and HER2 status subgroups using log-rank tests. Univariate and multivariate Cox proportional hazard regression models were used to obtain HRs and their respective 95% confidence intervals and estimate relative risk, and these approaches were applied to evaluate the relationship between potential covariates and either OS or BCSM. All statistical analyses were performed and probability of survival curves were generated using SPSS 19.0 (IBM Corporation, Armonk, NY). A two-sided P value \< 0.05 was considered statistically significant.
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![Weighted Kaplan-Meier curves of overall survival (OS) and breast-cancer--specific mortality (BCSM) on histological type.\
(**A**) OS is based on histological type. (**B**) BCSM is based on histological type. aHR: adjusted hazard ratio (adjusted for age at diagnosis, sex, race, grade, histology, stage, tumor stage, node stage, distant metastasis, laterality, ER, PR, Her2, subtype, radiotherapy, surgery and LN surgery).](srep45510-f1){#f1}

![Weighted Kaplan-Meier curves of overall survival (OS) and breast-cancer--specific mortality (BCSM) based on Her2 status in patients with PD-IDC.\
(**A**) OS is based on Her2 status. (**B**) BCSM is based on Her2 status.](srep45510-f2){#f2}

![Weighted Kaplan-Meier curves of overall survival (OS) and breast-cancer--specific mortality (BCSM) based on treatment in patients with PD-IDC.\
OS (**A**) and BCSM (**B**) are illustrated according to type of breast cancer operation. OS (**C**) and BCSM (**D**) are illustrated according to type of axillary operation.](srep45510-f3){#f3}

###### Patient characteristics within subgroups.

  Variables              IDC N = 179776(%)   PD-IDC N = 477(%)   P value\*
  --------------------- ------------------- ------------------- ------------
  Follow-up(months)        22.09 ± 13.73       22.21 ± 13.62          
  Age at diagnosis, y                                              0.151
   \<35                      3687(2.1)            15(3.1)             
   35--49                   35024(19.5)          100(21.0)            
   50--64                   68677(38.2)          164(34.4)            
   ≥65                      72388(40.3)          198(41.5)            
  Sex                                                            P \< 0.001
   Female                  178216(99.1)          458(96.0)            
   Male                      1560(0.9)            19(4.0)             
  Race                                                             0.564
   white                   141247(78.6)          379(79.5)            
   Black                   20387(111.3)           47(9.9)             
   Other                    18142(10.1)          51(10.7)             
  Grade                                                          P \< 0.001
   Well                     35041(19.5)           32(6.7)             
   Moderately               72244(40.2)          136(28.5)            
   Poorly                   63637(35.4)          262(54.9)            
   Undifferentiated          727(0.4)             3(0.6)              
   Unknown                   8127(4.5)            44(9.2)             
  Stage                                                          P \< 0.001
   I                        91242(50.8)          201(42.1)            
   II                       55848(31.1)          130(27.3)            
   III                      18512(10.3)         1116(24.3)            
   IV                        8719(4.8)            25(5.2)             
   Unknown                   5455(3.0)            5(1.0)              
  Tumor size                                                     P \< 0.001
   T0                        180(0.1)             12(2.5)             
   T1                      106807(59.4)          245(51.4)            
   T2                       51113(28.4)          116(24.3)            
   T3                        8636(4.8)            31(6.5)             
   T4                        7195(4.0)           63(13.2)             
   NA                        5845(3.3)            10(2.1)             
  Node stage                                                     P \< 0.001
   N0                      120154(66.8)          266(55.8)            
   N1                       41370(23.0)          119(24.9)            
   N2                        9306(5.2)           54(11.3)             
   N3                        5462(3.0)            36(7.5)             
   NX                        3484(1.9)            2(0.4)              
  Distant metastasis                                               0.358
   M0                      168093(93.5)          448(93.9)            
   M1                        8719(4.8)            25(5.2)             
   Bone                      5519(3.1)            8(1.7)              
   Brain                     623(0.3)             1(0.2)              
   Liver                     2302(1.3)            9(1.9)              
   Lung                      2828(1.6)            13(2.7)             
   Unknown                   2964(1.6)            4(0.8)              
  Laterality                                                       0.792
   Left                     91012(50.6)          250(52.4)            
   Right                    88552(49.3)          227(47.6)            
   Paired                    131(0.1)             0(0.0)              
   Bilateral                   34(0)              0(0.0)              
   Unknown                     47(0)              0(0.0)              
  ER                                                             P \< 0.001
   Negative                 33827(18.8)          173(36.3)            
   Positive                140777(78.3)          271(56.8)            
   Borderline                115 (0.1)            2(0.4)              
   Unknown                   5057(2.8)            31(6.5)             
  PR                                                             P \< 0.001
   Negative                 52290(29.1)          241(50.5)            
   Positive                121560(67.6)          201(42.1)            
   Borderline                277(0.2)             2(0.4)              
   Unknown                   5649(3.1)            33(6.9)             
  HER2                                                           P \< 0.001
   Negative                138627(77.1)          168(35.2)            
   Positive                 27962(15.6)          248(52.0)            
   Borderline                4190(2.3)            9(1.9)              
   Unknown                   8997(5.0)           52(10.9)             
  Subtype                                                        P \< 0.001
   HR+/Her2−               116697(64.9)          139(19.1)            
   HR+/Her2+                19188(10.7)          129(27.0)            
   HR−/Her2+                 8703(4.8)           115(24.1)            
   TN                       21670(12.1)           28(5.9)             
   Unknown                  13518(7.5)           66(13.8)             
  Radiotherapy                                                   P \< 0.001
   No                       88867(49.4)          336(70.4)            
   Yes                      89570(49.8)          140(29.4)            
   Unknown                   1339(0.7)            1(0.2)              
  Surgery                                                        P \< 0.001
   Mastectomy              970786(50.5)          63(83.0)             
   BCS                      72845(40.5)          396(13.2)            
   Other                    16145(9.0)            18(3.8)             
  LN surgery                                                     P \< 0.001
   SLNB                    124024(62.9)          257(53.9)            
   ALND                     50216(37.1)          215(45.1)            
   Unknown                   5536(3.1)            5(1.0)              
  Status                                                           0.006
   Alive                   166796(92.8)          427(89.5)            
   Dead                     12980(4.3)           50(10.5)             
   Breast cancer             7797(4.5)            34(7.4)             
   Other                     5183(0.3)            16(3.5)             

\*P values calculated by Pearson Chi squared testing; Bold if statistically significant, P \< 0.05. PD: paget's disease, IDC: invasive ductal carcinoma, y: years, BCS: breast-conserving surgery, HR: hormone receptor, TN: triple negative, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection.

###### Cox proportional hazards regression model analysis of overall survival and breast cancer-specific mortality in patients with PD-IDC.

  Variables                       OS            BCSM                           
  --------------------- ---------------------- ------- ----------------------- -------
  Age at diagnosis, y                                                          
   \<35                       Reference                       Reference            
   35--49                2.217(0.189, 26.056)   0.527    0.62(0.053, 7.261)     0.04
   50--64                1.527(0.145, 16.047)   0.725    0.525(0.031, 5.49)     0.602
   ≥65                   9.464(0.901, 99.457)   0.061   1.128(0.096, 13.693)    0.924
   Sex                    0.935(0.60, 2.34)     0.179    1.019(0.112, 3.636)    0.257
  Race                                                                         
   white                      Reference                       Reference            
   Black                 1.253(0.361, 4.351)    0.723    1.222(0.143, 4.307)    0.084
  Grade                                                                        
   Well                       Reference                       Reference            
   Moderately            0.853(0.087, 8.392)    0.892    220.2(0.0, 2.65E24)    0.835
   Poorly                1.825(0.198, 16.833)   0.595    508.2(0.0, 6.08E24)    0.81
   Undifferentiated      2.818(0.117, 67.64)    0.523   5090.7(0.0, 6.52E24)    0.742
  Stage                                                                        
   I                          Reference                       Reference            
   II                    3.867(0.708, 21.372)   0.118    0.752(0.05, 10.313)    0.831
   III                   4.33(0.544, 34.221)    0.166   7.703(0.547, 73.108)    0.096
   IV                    28.68(2.60, 316.29)    0.006   23.97(1.972, 291.19)    0.013
  Tumor size                                                                   
   T0                         Reference                       Reference            
   T1                    1972.8(0.0, 3.84E28)   0.798   1744.2(0.0, 1.24E39)    0.859
   T2                    1361.6(0.0, 2.69E28)   0.808   6428.7(0.0, 4.73E39)    0.835
   T3                    466.9(0.0, 9.28E28)    0.836    7134.5(0.0, 8.4E38)    0.867
   T4                    2131.4(0.0, 4.23E28)   0.796   7593.5(0.0, 5.54E39)    0.832
  Node stage                                                                   
   N0                         Reference                       Reference            
   N1                    0.893(0.245, 3.245)    0.863    1.515(0.402, 1.637)    0.216
   N2                     1.761(0.282, 11.0)    0.545    1.817(0.609, 2.063)    0.364
   N3                    2.133(0.374, 12.178)   0.394    2.565(0.297, 2.898)    0.193
  Distant metastasis                                                           
   M0                         Reference                       Reference            
   M1                    6.302(0.38, 104.521)   0.199    2.46(0.98, 61.898)     0.584
  Laterality                                                                   
   Left                       Reference                       Reference            
   Right                  1.215(0.56, 2.638)    0.623    1.139(1.062, 1.221)    0.435
  ER                                                                           
   Negative                   Reference                       Reference            
   Positive              0.839(0.096, 7.386)    0.874    0.324(0.579, 3.217)    0.336
  PR                                                                           
   Negative                   Reference                       Reference            
   Positive              0.414(0.139, 1.234)    0.113    0.553(0.151, 2.019)    0.37
  HER2                                                                         
   Negative                   Reference                       Reference            
   Positive              2.096(0.647, 6.785)    0.217   5.169(1.245, 21.456)    0.024
  Subtype                                                                      
   HR+/Her2-                  Reference                       Reference            
   HR+/Her2+             3711.4(0.0, 2.43E10)   0.305   11148.1(0.0, 2.96E11)   0.285
   HR-/Her2+             1081.3(0.0, 8.06E9)    0.387    559.9(0.0, 1.73E10)    0.473
   TN                    1576.7(0.0, 1.21E10)   0.363    589.9(0.0, 1.85E10)    0.469
  Radiotherapy                                                                 
   No                         Reference                       Reference            
   Yes                   1.098(0.472, 2.554)    0.827    0.976(0.541, 4.596)    0.404
  Surgery                                                                      
   BCS                        Reference                       Reference            
   Mastectomy            0.345(0.106, 1.124)    0.078    0.262(0.052, 1.311)    0.103
  LN surgery                                                                   
   ALND                       Reference                       Reference            
   SLNB                  3.317(1.136, 9.687)    0.028    3.397(0.952, 12.11)    0.059

PD: paget's disease, IDC: invasive ductal carcinoma, y: years, BCS: breast-conserving surgery, HR: hormone receptor, TN: triple negative, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection. aHR: adjusted hazard ratio (adjusted for age at diagnosis, sex, race, grade, stage, tumor stage, node stage, distant metastasis, laterality, ER, PR, Her2, subtype, radiotherapy, surgery and LN surgery), CI: confidence interval.
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